
CDMO - April 15, 2025
New European CDMO launched, with site in Sweden
A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions, has launched with an integrated network across Europe.

Pharma article - April 2, 2025
AI model predicts multi-resistance in bacteria
The new study, conducted by researchers at the Chalmers University of Technology, the University of Gothenburg, and the Fraunhofer-Chalmers Centre, shows that antibiotic resistance is more easily transmitted between genetically similar bacteria and mainly occurs in wastewater treatment plants and inside the human body.

Agreement - March 28, 2025
OncoZenge in agreement for the commercialization of BupiZenge in Europe
The company has entered into a binding agreement with Molteni Farmaceutici regarding exclusive rights to commercialize BupiZenge in Europe.

CDMO - March 27, 2025
Holding a steady course through troubled waters
Half a decade into the 2020’s, the world finds itself in a turbulent era, to say the least. This is true geopolitically and financially, not to mention the natural disasters that rock the boat for people and businesses worldwide.

Drug Development Pharma - March 24, 2025
New findings about Elypta’s urine test in kidney cancer follow-up
Elypta has announced that findings from the international AURORAX-0087A (AUR87A) study, the largest diagnostics study ever conducted on the most common type of kidney cancer, were presented today in a Plenary Game Changer Session at the 2025 European Association of Urology Congress.

Agreement - March 24, 2025
Novo Nordisk gains rights to China-based The United Laboratories’ ‘triple G’ obesity drug
Novo Nordisk and the United Laboratories International Holdings Limited (TUL)'s wholly-owned subsidiary, The United Bio-Technology (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.